Major Depressive Disorder Clinical Trial
— CO-MEDOfficial title:
Combining Medications to Enhance Depression Outcomes
This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.
Status | Completed |
Enrollment | 665 |
Est. completion date | September 2009 |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Seeking treatment at the primary or specialty care site, and be planning to continue living in the area of that clinic for the duration of the study - Meets clinical criteria for nonpsychotic MDD, recurrent (with the current episode being at least 2 months in duration), or chronic (current episode greater than 2 years) as defined by a clinical interview and confirmed by the MINI International Neuropsychiatric Interview (MINI) - Screening 17 item HRSD score of 16 or greater - Treatment with antidepressant medication combinations is clinically acceptable - Patient with and without current suicidal ideation may be included in the study as long as outpatient treatment is clinically appropriate Exclusion Criteria: - Pregnant or breastfeeding - Plans to become pregnant over the ensuing 8 months following study entry or are sexually active and not using adequate birth control - History (lifetime) of psychotic depression, schizophrenia, bipolar (I, II, or NOS), schizoaffective, or other Axis I psychotic disorders - Current psychotic symptom(s) - History (within the last 2 years before study entry) of anorexia or bulimia - Current primary diagnosis of obsessive compulsive disorder - Current substance dependence that requires inpatient detoxification or inpatient treatment - Requiring immediate hospitalization for a psychiatric disorder - Definite history of intolerance or allergy (lifetime) to any protocol medication - History of clear nonresponse to an adequate trial of an FDA-approved monotherapy in the current MDE if recurrent, or during the last 2 years before study entry if chronic - History of clear nonresponse to an adequate trial of any study medication used as a monotherapy, or to one or more of the protocol combinations in the current or any prior MDE - Currently taking any of the study medications at any dose - Having taken Prozac (fluoxetine) or an MAOI in the 4 weeks before study entry - Presence of an unstable general medical condition (GMC) that will likely require hospitalization or to be deemed terminal (life expectancy less than 6 months after study entry) - Currently taking medications or have GMCs that contraindicate any study medications (e.g., seizure disorder) - Requiring medications for GMCs that contraindicate any study medication - Epilepsy or other conditions requiring an anticonvulsant - Lifetime history of having a seizure including febrile or withdrawal seizures - Receiving or have received vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or other somatic antidepressant treatments - Currently taking or having taken within the 7 days before study entry any of the following exclusionary medications: antipsychotic medications, anticonvulsant medications, mood stabilizers, or central nervous system stimulants (antidepressant medication used for the treatment of depression or other purposes such as smoking cessation or pain are excluded since these agents may interfere with the testing of the major hypotheses under study) - Uncontrolled narrow angle glaucoma - Taking thyroid medication for hypothyroidism may be included only if stable on the medication for 3 months - Using agents within the 7 days before study entry that are potential augmenting agents (e.g., T3 in the absence of thyroid disease, SAMe, St. John's Wort, lithium, buspirone) - Therapy that is depression-specific |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | General Psychiatric Ambulatory Clinic | Ann Arbor | Michigan |
United States | UNC Chapel Hill Adult Diagnostic & Treatment Clinic | Chapel Hill | North Carolina |
United States | Northwestern Psychiatric Outpatient Treatment Care Center | Chicago | Illinois |
United States | UT Southwestern Family Medicine Clinic | Dallas | Texas |
United States | Harbor UCLA Family Health Care Center | Harbor City | California |
United States | UCLA Internal Medicine Clinic | Los Angeles | California |
United States | Vine Hill Community Clinic | Nashville | Tennessee |
United States | Irving Goldman Primary Care at North Shore Hospital | New York | New York |
United States | Bellefield Clinic of WPIC | Pittsburgh | Pennsylvania |
United States | VCU Outpatient Psychiatry Clinic | Richmond | Virginia |
United States | MGH/Northshore Medical Center (Salem Psychiatric Facility) | Salem | Massachusetts |
United States | Veterans Affairs Medical Center/FIRM Primary Care Clinic | San Diego | California |
United States | Laureate Psychiatric Clinic and Hospital | Tulsa | Oklahoma |
United States | Tuscalossa VA Mental Health Clinic | Tuscaloosa | Alabama |
United States | Clinical Research Institute | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health (NIMH) |
United States,
Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR. Combining medications to enhance depression outcomes (CO-MED): acute and long-term o — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quick Inventory of Depressive Symptoms | Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). | Measured at Month 7 | No |
Secondary | Quality of Life Inventory | The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. | Measured at Month 7 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |